Insulin therapy, vital for diabetes management, is often misunderstood. It's not a sign of failure or addiction, nor does it ...

But the company has just presented early stage data showing the formulation to be as effective as injectable insulin – and says a future advance in drug delivery could still make it a reality.

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Its effect lasts for about two to three hours, closely resembling the body’s own response to insulin. This is the first and only non-injectable insulin to be developed for patients of both type ...

Managing diabetes involves daily blood sugar monitoring, specialized devices, and medications like insulin, so understanding ...

Learning a pet has diabetes can be a shock. Sadly, about 20% of diabetic cats and dogs are euthanized within a year of ...

Lilly and EVA Pharma receive Egyptian Drug Authority approval for insulin glargine injection and release of locally manufactured insulin in Egypt: Indianapolis Thursday, December ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Medicare Part D plans cover injectable insulin not associated with the use of durable insulin pumps, which are covered under Part B. Considering nearly 30% of adults ages 65 and older have ...

“Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon ...

(RTTNews) - Eli Lilly and Company said the Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). The ...